Kit Simpson to HIV-1
This is a "connection" page, showing publications Kit Simpson has written about HIV-1.
Connection Strength
1.153
-
Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden. AIDS Care. 2014 Apr; 26(4):466-75.
Score: 0.382
-
Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health Qual Life Outcomes. 2013 Oct 03; 11:164.
Score: 0.382
-
Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res Hum Retroviruses. 2014 Aug; 30(8):753-68.
Score: 0.101
-
Cost of treatment in a US commercially insured, HIV-1-infected population. PLoS One. 2014; 9(5):e98152.
Score: 0.100
-
Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-na?ve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
Score: 0.098
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
Score: 0.060
-
Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997 Jul; 12(1):54-66.
Score: 0.031